- Home
- AMBO vs ONCT Comparison
AMBO vs ONCT Comparison
Compare AMBO & ONCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- ONCT
- Stock Information
- Founded
- AMBO 2000
- ONCT N/A
- Country
- AMBO United States
- ONCT United States
- Employees
- AMBO N/A
- ONCT N/A
- Industry
- AMBO Other Consumer Services
- ONCT Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- ONCT Health Care
- Exchange
- AMBO Nasdaq
- ONCT Nasdaq
- Market Cap
- AMBO 5.0M
- ONCT 4.3M
- IPO Year
- AMBO 2010
- ONCT N/A
- Fundamental
- Price
- AMBO $1.47
- ONCT $1.14
- Analyst Decision
- AMBO
- ONCT Buy
- Analyst Count
- AMBO 0
- ONCT 3
- Target Price
- AMBO N/A
- ONCT $10.00
- AVG Volume (30 Days)
- AMBO 15.7K
- ONCT 89.1K
- Earning Date
- AMBO 11-29-2024
- ONCT 11-06-2024
- Dividend Yield
- AMBO N/A
- ONCT N/A
- EPS Growth
- AMBO N/A
- ONCT N/A
- EPS
- AMBO N/A
- ONCT N/A
- Revenue
- AMBO $9,163,000.00
- ONCT $2,161,000.00
- Revenue This Year
- AMBO N/A
- ONCT $113.76
- Revenue Next Year
- AMBO N/A
- ONCT N/A
- P/E Ratio
- AMBO N/A
- ONCT N/A
- Revenue Growth
- AMBO N/A
- ONCT 227.92
- 52 Week Low
- AMBO $1.00
- ONCT $1.03
- 52 Week High
- AMBO $6.30
- ONCT $13.20
- Technical
- Relative Strength Index (RSI)
- AMBO 47.36
- ONCT 39.40
- Support Level
- AMBO $1.33
- ONCT $1.03
- Resistance Level
- AMBO $1.49
- ONCT $1.20
- Average True Range (ATR)
- AMBO 0.15
- ONCT 0.15
- MACD
- AMBO -0.00
- ONCT 0.00
- Stochastic Oscillator
- AMBO 44.00
- ONCT 15.49
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.